The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Fighting Cardiac Fibrosis with CAR T Cells
Abstract
Autologous chimeric antigen receptor T cells, which are engineered to bind and kill cells that express a specific antigen, are effective in the treatment of certain cancers. A recent study involving a mouse model shows that CAR T cells can be generated in vivo and may reduce fibrosis after myocardial injury.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“On the other hand, other efforts to target fibrogenic cells in the heart by targeting cell surface FAP-1 (fibroblast activating protein) are very encouraging, and may be adaptable to liver disease.147,148”
From An integrated view of anti-inflammatory and antifibrotic targets for the treatment of NASH (2023) · cites this paper as [147]
Citations
Cites
Fibrosis–a common pathway to organ injury and failure
Rockey, D. C., Bell, P. D., & Hill, J. A. (2015) · New England Journal of Medicine · doi:10.1056/nejmra1300575 · Cited by 1,428
CAR T cells produced in vivo to treat cardiac injury
Rurik, J. G., Tombácz, I., Yadegari, A., Méndez Fernández, P. O., Shewale, S. V., Li, L., Kimura, T., Soliman, O. Y., Papp, T. E., Tam, Y. K., et al. (2022) · Science · doi:10.1126/science.abm0594 · Cited by 1,400
Senolytic CAR T cells reverse senescence-associated pathologies
Amor, C., Feucht, J., Leibold, J., Ho, Y.-J., Zhu, C., Alonso-Curbelo, D., Mansilla-Soto, J., Boyer, J. A., Li, X., Giavridis, T., et al. (2020) · Nature · doi:10.1038/s41586-020-2403-9 · Cited by 1,098
Self-citationCAR T Cells Produced in vivo to Treat Cardiac Injury
Rurik, J. G., Tombácz, I., Yadegari, A., Fernández, P. O. M., Shewale, S. V., Li, L., Kimura, T., Soliman, O. Y., Papp, T. E., Tam, Y. K., et al. (2023) · Book Publisher International (a part of SCIENCEDOMAIN International) · doi:10.9734/bpi/mono/978-81-19039-63-0/ch19 · Cited by 929
CAR T Cells Produced in vivo to Treat Cardiac Injury
Rurik, J. G., Tombácz, I., Yadegari, A., Fernández, P. O. M., Shewale, S. V., Li, L., Kimura, T., Soliman, O. Y., Papp, T. E., Tam, Y. K., et al. (2023) · HAL · Cited by 926
Targeting cardiac fibrosis with engineered T cells
Aghajanian, H., Kimura, T., Rurik, J. G., Hancock, A. S., Leibowitz, M. S., Li, L., Scholler, J., Monslow, J., Lo, A., Han, W., et al. (2019) · Nature · doi:10.1038/s41586-019-1546-z · Cited by 801
Fibrosis — A Common Pathway to Organ Injury and Failure
(2015) · New England Journal of Medicine · doi:10.1056/nejmc1504848 · Cited by 284
Better living through chemistry: CRISPR/Cas engineered T cells for cancer immunotherapy
Wellhausen, N., Agarwal, S., Rommel, P. C., Gill, S. I., & June, C. H. (2021) · Current Opinion in Immunology · doi:10.1016/j.coi.2021.10.008 · Cited by 28
Cited by
An integrated view of anti-inflammatory and antifibrotic targets for the treatment of NASH
Tacke, F., Puengel, T., Loomba, R., & Friedman, S. L. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2023.03.038 · Cited by 321
Self-citationTreatment of cardiac fibrosis: from neuro-hormonal inhibitors to CAR-T cell therapy
Morfino, P., Aimo, A., Castiglione, V., Gálvez‐Montón, C., Emdin, M., & Bayés‐Genís, A. (2022) · Heart Failure Reviews · doi:10.1007/s10741-022-10279-x · Cited by 72
Antifibrotic therapies for metabolic dysfunction-associated steatotic liver disease
Schwabe, R. F., Tacke, F., Sugimoto, A., & Friedman, S. L. (2025) · JHEP Reports · doi:10.1016/j.jhepr.2025.101421 · Cited by 70
Self-citationHuston, P. (2022) · Frontiers in Physiology · doi:10.3389/fphys.2022.904107 · Cited by 42
“It has recently been estimated that 40% of all deaths in the industrialized world is due to fibrosis (Friedman, 2022).”
BackgroundAntifibrotic effects of sodium-glucose cotransporter-2 inhibitors: A comprehensive review
Shakour, N., Karami, S., Iranshahi, M., Butler, A. E., & Sahebkar, A. (2023) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2023.102934 · Cited by 35
Metadata
- Authors
- Friedman, S. L.
- Affiliations
- Icahn School of Medicine at Mount Sinai (US)
- Corresponding author
- Friedman, Scott L.
- ORCID
- Friedman, Scott L.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2022-04-21
- Volume
- 386
- Issue
- 16
- Pages
- 1576-1578
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4224285902
- Cited by
- 28
- References
- 7
- Citations by year
- 2026: 4 · 2025: 10 · 2024: 4 · 2023: 4 · 2022: 6
- FWCI
- 4.21
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac Fibrosis and Remodeling
- Health Sciences › Medicine › Oncology › CAR-T cell therapy research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Congenital heart defects research
- Keywords
- myocardial fibrosis, chimeric antigen receptor T cells, CAR T-cell therapy, myocardial injury, mouse model
- MeSH terms
- Receptors, Chimeric Antigen, Fibrosis, Heart Diseases, Humans, T-Lymphocytes, Immunotherapy, Adoptive
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Fighting Cardiac Fibrosis with CAR T Cells. https://app.cochat.ai/papers/10.1056/nejmcibr2201182
- The paper
- Friedman, S. L. (2022). Fighting Cardiac Fibrosis with CAR T Cells. New England Journal of Medicine. https://doi.org/10.1056/nejmcibr2201182
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.